- Home
- All Stock List
- BSE
- Concord Biotech Ltd Share Price
1,711.50
-8.15 (-0.47%)
-
Underperforms Index
8.2%
Return (1Y)
Underperformed BSE Healthcare by 12.46%
-
More Volatile
3.22%
Standard Deviation (1Y)
Higher than BSE Healthcare by 2.16%
-
Not so consistent
6/12
Months
underperformed BSE Healthcare
-
AxisDirect View
No View
2,658
1,327
News & Announcements
-
Concord Biotech gets US FDA nod for marketing multiple sclerosis drug Teriflunomide
09 - Apr - 2025 12:00 | 13 days ago
Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.
This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market, Concord Biotech said in a statement.
According to IQVIA, the market size of Teriflunomide tablets is approximately $402 million in the US, and the global market size is approximately $908 million, indicating significant opportunities for expansion in the US and the global market.
Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment.
The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25.
The scrip shed 0.17% to currently trade at Rs 1595.10 on the BSE.
Powered by Capital Market - Live News
-
-
Concord Biotech invest Rs 6.09 cr in Clean Max
49 days ago
Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka.
Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency.
Powered by Capital Market - Live News
-
-
Concord Biotech invest Rs 6.09 cr in Clean Max
49 days ago
Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka.
Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency.
Powered by Capital Market - Live News
-
This rebound follows a steep decline of 28.15% over the preceding seven trading sessions, triggered by the company's disappointing third-quarter financial results for the 2025 fiscal year (Q3FY25).
The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. Profit before tax (PBT) fell 2% YoY to Rs 75.92 crore during the quarter.
EBITDA stood at Rs 98 crore, registering de-growth of 8% compared with Rs 105.9 crore in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24.
Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.
Powered by Capital Market - Live News
-
Concord Biotech gets US FDA nod for marketing multiple sclerosis drug Teriflunomide
09 - Apr - 2025 12:00 | 13 days ago
Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.
This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market, Concord Biotech said in a statement.
According to IQVIA, the market size of Teriflunomide tablets is approximately $402 million in the US, and the global market size is approximately $908 million, indicating significant opportunities for expansion in the US and the global market.
Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment.
The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25.
The scrip shed 0.17% to currently trade at Rs 1595.10 on the BSE.
Powered by Capital Market - Live News
-
-
Concord Biotech invest Rs 6.09 cr in Clean Max
49 days ago
Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka.
Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency.
Powered by Capital Market - Live News
-
This rebound follows a steep decline of 28.15% over the preceding seven trading sessions, triggered by the company's disappointing third-quarter financial results for the 2025 fiscal year (Q3FY25).
The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. Profit before tax (PBT) fell 2% YoY to Rs 75.92 crore during the quarter.
EBITDA stood at Rs 98 crore, registering de-growth of 8% compared with Rs 105.9 crore in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24.
Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.
Powered by Capital Market - Live News
-
Concord Biotech gets US FDA nod for marketing multiple sclerosis drug Teriflunomide
09 - Apr - 2025 12:00 | 13 days ago
Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.
This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market, Concord Biotech said in a statement.
According to IQVIA, the market size of Teriflunomide tablets is approximately $402 million in the US, and the global market size is approximately $908 million, indicating significant opportunities for expansion in the US and the global market.
Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment.
The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25.
The scrip shed 0.17% to currently trade at Rs 1595.10 on the BSE.
Powered by Capital Market - Live News
-
-
Concord Biotech invest Rs 6.09 cr in Clean Max
49 days ago
Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka.
Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency.
Powered by Capital Market - Live News
-
-
Concord Biotech invest Rs 6.09 cr in Clean Max
49 days ago
Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka.
Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency.
Powered by Capital Market - Live News
-
This rebound follows a steep decline of 28.15% over the preceding seven trading sessions, triggered by the company's disappointing third-quarter financial results for the 2025 fiscal year (Q3FY25).
The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. Profit before tax (PBT) fell 2% YoY to Rs 75.92 crore during the quarter.
EBITDA stood at Rs 98 crore, registering de-growth of 8% compared with Rs 105.9 crore in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24.
Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.
Powered by Capital Market - Live News
Stock Trivia
FII shareholding in Concord Biotech Ltd has increased by 12.2% since past 3 Months
FII shareholding in Concord Biotech Ltd has increased by 44.25% since past 1 Year
FII shareholding in Concord Biotech Ltd has increased by 12.2% since past 3 Months
MF shareholding in Concord Biotech Ltd has increased by 6.01% since past 3 Months
FII shareholding in Concord Biotech Ltd has increased by 44.25% since past 1 Year
FII shareholding in Concord Biotech Ltd has increased by 12.2% since past 3 Months
FII shareholding in Concord Biotech Ltd has increased by 44.25% since past 1 Year
